Application of 1 type receptor antagonist of angiotensin II in treating tumour
An angiotensin and receptor antagonist technology, applied in the field of medicine, can solve problems such as leukopenia, patients' susceptibility to infectious diseases, and bleeding
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0036] Embodiment 1: the preparation of therapeutic agent
[0037] The therapeutic agents used in the present invention are commercially available various sartan drugs, which are dissolved in phosphate buffered saline (PBS), stored in a refrigerator at 4° C., and diluted into working solutions of different concentrations with culture medium when used. Losartan: Tablet, produced by Hangzhou Modong Pharmaceutical Co., Ltd., approved by the State Drug Administration: X20000371, batch number: 01067; : Capsule, produced by Guangdong Hexin Pharmaceutical Co., Ltd., Zhunzi: X20000546; Eprosartan: tablet, produced by Hangzhou Keben Pharmaceutical Co., Ltd.; candesartan: tablet, produced by Hangzhou Keben Pharmaceutical Co., Ltd. ; Telmisartan: tablet, Zhejiang Jinliyuan Pharmaceutical Co., Ltd., approved by the State Drug Administration: H20041252; Olmesartan: tablet, produced by Hangzhou Keben Pharmaceutical Co., Ltd.
Embodiment 2
[0039] 1. Inhibitory effect of angiotensin II type 1 receptor antagonist on the growth of human liver cancer HepG2 cells in vitro
[0040] Tested cells: human liver cancer Hep G2 cells
[0041] Drugs tested: losartan, valsartan, irbesartan, eprosartan, candesartan, telmisartan, olmesartan
[0042] Experimental procedure: After the cells in the logarithmic growth phase were digested with trypsin, the cell concentration was adjusted to 5×10 with RPMI 1460 full medium 7 / L, 100 μL (5×10 3 ), at 37°C, 5% CO 2 Incubate overnight at saturated humidity. On the next day, add 100 μL of 500 μmol / L losartan, 100 μL of 500 μmol / L valsartan, 100 μL of 500 μmol / L irbesartan, 100 μL of 500 μmol / L eprosartan, 100 μL of 500 μmol / L candesartan, 500 μmol / L telmisartan 100μL, 500μmol / L olmesartan 100μL, with no drug as the control group, with 25mg / L cisplatin solution (DDP) as the positive control group, each group set 4 duplicate wells, cultured 24 , 48, 72h, discard the suspension 4-6h be...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com